We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Destiny Pharma Plc | DEST | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
27.50 | 25.00 | 27.50 | 25.50 | 27.50 |
Industry Sector |
---|
PHARMACEUTICALS & BIOTECHNOLOGY |
Top Posts |
---|
Posted at 28/3/2024 11:47 by john henry Dest have enough cash until Q2 2025.My guess is that they would conclude the JV before raising further funds. Saying that funding requirements will depend on the upfront cash payment from the JV. |
Posted at 28/3/2024 11:28 by beatme1 Dest has decided to go private and are following in c4xd footsteps |
Posted at 05/3/2024 22:13 by bones698 So educational I take it your under water here amerpoo. You have picked quite a few dogs recently with apta, dest etc. Crawl back into your hole gobshjte |
Posted at 05/3/2024 14:11 by bones698 Marvel man there is one real bones and an imposter with 699 after his name who I upset because I showed everyone he was an idiot and no trolls the boards using that name. So be careful which you follow an dlok at.As for dest I said sub 30p and it had got there and looks likely to head lower without news. It was overvalued for where it was upto and the cash requirements and time it will take. That hasn't changed, be careful with biotech shares they are cash hungry in a market where cash isn't available. As for my AGL all mine are free as I bought near the lows and sold on the spike keeping the rest free. Not many at win such a position |
Posted at 08/2/2024 10:03 by carlisle44 Where can one find a list of major Dest Investors ie 3% plus? Checked company website bit I cannot find one.TIA for any assistance |
Posted at 05/2/2024 14:33 by john henry Candid on LSEThe RNS was indeed positive but some may have perceived the possibility of a bridging phase 2 trial by Sebela as a delay. This might not even happen as the RNS stated that Sebela are evaluating it and MAY decide to run a bridging phase 2 before doing the phase 3. I think they might in fact evaluate it and then go into phase 3 after doing a simple test to show equivalence as there is already an FDA agreement in place for exactly this reason. (DEST presentation 2023): Process development ongoing to produce oral capsule product for Phase 3 — FDA agreed to simple disintegration test to demonstrate equivalence between Phase 2 and Phase 3 product — Expected to have capsules ready for Phase 3 H2 2023 Therefore Sebela may only need to before a simple test to demonstrate equivalence and M3 is back on track. Dest having been working on an oral capsule for months. |
Posted at 04/2/2024 17:13 by mam fach All tipsters the same. Buy before they Tip then sell before they advise stop loss.Had all this hype about new CEO yet no apparent progress in negotiations. What a surprise it would be to get amazing news. DEST do have amazing products in the pipeline. Hoping price will start to recover from Monday. GLA |
Posted at 02/2/2024 21:48 by john henry 82k and a 54k dumped earlier doors yesterday.No wonder Dest is getting hit hard, someone is dumping stock big time. Price could rebound strong once they are out. Nearly 6M traded the last few days |
Posted at 02/2/2024 14:29 by banshee JH The reformulation is under the remit i.e authority and control - of Dest, following their own review. The only reference to Sebal being involved is that that have had/agreed to change their manufacturing and control contract alongside Dest. It may be that they are happy to simply rerun phase 2, but also possible this will trigger an internal re-review of the project if that is the option recommended. |
Posted at 30/12/2023 17:17 by xcap1 So doing a bit of research, I find it puzzling why we are not de listing and listing on the US markets. I just research (randomly ) for comparison purposes a number of pre clinical stage 2 bio pharma companies . I was shocked to find the valuation gap with DEST. So ticker first then mcap in billions! Yes billions and all have millions in cash on their balance to progress the clinical trials CBAY $2.7bRCKT $2.7bIMVT $6bVRDN $1.15bDEST $85millionApologises if I've missed 'the obvious' but our valuation is a nonsense Any |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions